CZECRIN

What CZECRIN does

CZECRIN is a Czech national research infrastructure that supports academic (non-commercial) clinical trials across the Czech Republic, operating as a distributed network of 18 healthcare facilities and 10 disease-oriented networks (DONETs) covering oncology, epilepsy, stroke, infectious diseases, perinatology, anesthesiology/intensive care, interventional cardiology, neurodegeneration, and pediatrics. Founded on 21 March 2014 by the Ministry of Education, Youth and Sports under the legal umbrella of Masaryk University in Brno, CZECRIN is the official Czech national node of ECRIN-ERIC and is part of the Czech National Roadmap for Large RDI Infrastructures and the ESFRI Roadmap.

Its core platform combines three pillars: a National Centre for Clinical Studies providing methodological, regulatory, monitoring, biostatistics, and data management support; CZECRIN Academy for clinical research education and certification; and the DONET networks coordinating domain-specific trial activity. Underlying infrastructure includes REDCap-based electronic data capture, Phase I clinical trial units for first-in-human studies, GMP-certified ATMP manufacturing facilities (ACIU MUNI and CTEF-cGMP FNUSA-ICRC), and the RaPhe regulatory and pharmacoeconomics advisory unit. Notable outputs include 92 supported clinical studies, 1600+ patients enrolled, 155 scientific publications, 26 H2020 projects, and 4 innovative ATMP products in development, including MyDendrix, which received the first ATMP hospital exemption granted in the Czech Republic.

CZECRIN is funded primarily through public sources — the MŠMT VVI CZECRIN project (LM2023049) and European structural funds (CZECRIN_PRO PACIENTY) — and provides its services as a publicly funded national resource rather than on a commercial basis. Go-to-market is community-led: it acquires collaborators via network building, conference participation, and a public REDCap registration form, with no commercial pricing model. End users are academic clinical researchers, hospital research departments, rare disease patients (especially pediatric oncology), and international research consortia connected through ECRIN-ERIC.

Name

CZECRIN

Legal name

Masarykova univerzita

Website

https://czecrin.cz

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

CZECRIN is a Czech national research infrastructure supporting academic clinical trials across 18 partner hospitals and 10 disease networks, operating as the Czech national node of ECRIN-ERIC. It serves academic researchers, hospital trial departments, and rare disease patients through trial coordination, GMP ATMP manufacturing, and regulatory support.

Ownership category

akta.pro rank

Product category

Clinical Research Infrastructure

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Health Services (8000)

akta.pro primary industry

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

akta.pro secondary industries

Investigator & Site Training / GCP Support (HLAGACAF), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA), Clinical Research Support (CRC/CTA) (EDAOAJAO), Decentralized/Hybrid Trial Enablement (DCT) Platforms (HLACAOAL)

Keywords

• Clinical research infrastructure
• Academic clinical trials
• ATMP manufacturing
• Clinical trial coordination
• Disease-oriented networks

Headquarters

HQ city

Brno

HQ country

Czechia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Public Research Infrastructure Funding: CZECRIN is funded through Ministry of Education, Youth and Sports (MEYS/MŠMT) via large research infrastructure support programs. It receives state budget funding through project VVI CZECRIN (LM2023049) and European structural funds (CZECRIN_PRO PACIENTY project). The infrastructure does not generate commercial revenue but provides its services as a publicly funded national research resource.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels11 records

Core offering

CZECRIN is a national clinical research infrastructure that provides comprehensive methodological, regulatory, and operational support for non-commercial (academic) clinical trials across the Czech Republic. It operates a distributed network of 18 clinical sites organized into ten disease-oriented networks (DONETs), provides GMP-certified manufacturing for advanced therapy medicinal products (ATMPs), and delivers education and certification through the CZECRIN Academy. As the Czech national node of ECRIN-ERIC, it integrates domestic research capacity into pan-European multi-centre academic trials.

Product overview

CZECRIN is a national clinical research infrastructure that provides comprehensive support for clinical trials throughout their lifecycle. The organization operates as a platform-plus-services model consisting of three main pillars: the National Centre for Clinical Studies (providing methodological and operational support), CZECRIN Academy (education and certification), and Networks (DONETs for disease-specific research networks). The infrastructure includes specialized technological units for GMP-certified ATMP manufacturing (CZECRIN PharmTech, GMP Core Units), advisory services (RaPhe for regulatory and pharmacoeconomics), Phase I clinical units, and connections to European networks via ECRIN-ERIC. CZECRIN supports approximately 18 healthcare facilities, manages 92 clinical trials, participates in 26 H2020 projects, and has enrolled over 1,600 patients in clinical studies.

Differentiator

Problem solved

Functional benefit

Brands

• Národní centrum klinických studií (Clinical Trial National Centre): A national centre providing methodological and practical support for preparation and implementation of clinical trials across the Czech Republic.
• CZECRIN Academy
• DONETs
• Jednotky fáze I (Phase I Units)
• CZECRIN PharmTech / GMP Core Units
• RaPhe (Regulatory Advisory and Pharmacoeconomics Unit)

Products and services

• National Centre for Clinical Studies (Národní centrum klinických studií) Central pillar of CZECRIN providing methodological and practical support for the preparation and implementation of clinical trials across the Czech Republic, including study coordination, start-up support, and regulatory guidance for academic and clinical research teams within the CZECRIN network.
• CZECRIN Academy Educational and certification program for clinical research professionals offering courses and practical training for investigators, coordinators, study nurses, and students to strengthen quality and standards in clinical trials.
• DONETs (Disease-Oriented Networks) Network infrastructure connecting clinical sites and researchers focused on specific disease areas (oncology, epilepsy, stroke, pediatrics, infectious diseases, anesthesiology/intensive care, perinatology, interventional cardiology, neurology, pneumology) to support multi-site academic clinical research within the Czech Republic.
• GMP Core Units (ACIU MUNI and CTEF-cGMP FNUSA-ICRC) Good Manufacturing Practice-certified facilities dedicated to production of Advanced Therapy Medicinal Products (ATMPs) such as cell and gene therapies, supporting non-commercial clinical manufacturing for academic trials.
• Phase I Units (Jednotky fáze I) Specialized facilities for early-phase clinical evaluation including first-in-human studies, providing safe and highly controlled environments for demanding early-phase trials.
• CZECRIN PharmTech Pharmaceutical technology laboratories supporting advanced therapy development and manufacturing activities for clinical research within the CZECRIN network.
• RaPhe - Regulatory Advisory and Pharmacoeconomics Unit Advisory service providing expertise in regulatory strategies, health economics, pharmacoeconomic evaluations, and HTA design, supporting the translation of clinical research findings into cost-effective healthcare interventions.
• Expertise and Services (Feasibility, Monitoring, Statistics, Data Management, Methodology) Comprehensive support package covering feasibility assessments, study preparation, monitoring, biostatistics, electronic data management (REDCap), methodology, and consultations for clinical research projects across the network.
• MyDendrix Cellular immunotherapy (dendritic cell-based) developed through academic research within the CZECRIN/CREATIC ecosystem for pediatric and adolescent patients with high-risk tumors, granted the first hospital exemption for an Advanced Therapy Medicinal Product in the Czech Republic.

Quantifiable outcome

• 1600+ patients enrolled in clinical trials through the CZECRIN network
• +4 more outcomes

Named customers17 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

14 partnerships are on record, tiered core and minor.

• ECRIN-ERIC (European Clinical Research Infrastructure Network)coreStrategic or Co-development Partner · 21 March 2014CZECRIN is the Czech national node of ECRIN-ERIC, enabling integration of Czech clinical research capacity into the pan-European research infrastructure. Through this membership, Czech researchers can participate in and coordinate international multi-centre non-commercial clinical trials. CZECRIN represents the Czech Republic with full membership in ECRIN-ERIC and is part of the ESFRI Roadmap.
• Masaryk University (MUNI)coreStrategic or Co-development Partner · 21 March 2014Masaryk University is the host institution and legal entity of CZECRIN. Established by decision of the Ministry of Education, Youth and Sports, with Masaryk University as the host and St. Anne's University Hospital as the founding partner. The university provides institutional infrastructure, administrative support, and academic research environment for CZECRIN operations.
• FNUSA - St. Anne's University Hospital in BrnocoreStrategic or Co-development PartnerFNUSA is the founding partner of CZECRIN and home to the ICRC (International Center for Clinical Trials). It provides essential support in clinical site network coordination, technical and administrative services. FNUSA also hosts CTEF-cGMP manufacturing unit and is a national reference centre for rare neurological diseases through ERN-RND.
• CREATIC (Centre of Excellence for Advanced Therapy and Immunotherapy)coreStrategic or Co-development PartnerCZECRIN is an integral part of the CREATIC Centre of Excellence at Masaryk University's Faculty of Medicine. CREATIC focuses on research, development, and GMP manufacturing of ATMPs (cell and gene therapies) for patients with rare and serious diseases. CZECRIN supports the clinical trial and regulatory components within this ecosystem.
• ERN EpiCARE (European Reference Network for Rare and Complex Epilepsies)minorStrategic or Co-development PartnerCZECRIN | EPI network participates in ERN EpiCARE, connecting Czech epileptology centres with European reference centres for rare epilepsies. The network also collaborates with ERN-RND for neurodegenerative diseases.
• ERN-RND (European Reference Network for Rare Neurological Diseases)minorStrategic or Co-development PartnerCZECRIN | NEURODEGEN network is established at FNUSA, which is a member of ERN-RND and acts as a national reference centre for rare neurodegenerative disorders. The network contributes to the ERN-RND Registry and European data-sharing initiatives.
• Motol University Hospital (FN Motol)minorStrategic or Co-development PartnerMotol University Hospital is a major clinical trial site and member of CZECRIN. Its Clinical Trials Department provides administrative support for commercial and academic studies and works closely with CZECRIN on trial coordination.
• Masaryk Institute of Oncology (MOÚ)coreStrategic or Co-development PartnerKey partner of CZECRIN hosting the Centre for Precision Oncology and leading the GENESIS national molecular tumor board platform. It is a key centre for precision oncology clinical trials and coordinates the GENESIS project connecting 10 oncology centres.
• IKEM - Institute for Clinical and Experimental MedicineminorStrategic or Co-development PartnerIKEM is a member of the CZECRIN network, contributing specialized clinical and research capacity in cardiovascular and transplant medicine.
• University Hospital Brno (FN Brno)minorStrategic or Co-development PartnerFN Brno provides a Clinical Trials Department with administrative support across hospital clinics, managing contracts, budgets, payments, and study billing across all its departments.
• University Hospital Ostrava (FN Ostrava)minorStrategic or Co-development PartnerPart of CZECRIN since 2016, FN Ostrava's Centre for Clinical Studies serves as a link between study sponsors and investigators, functioning as administrative, financial, and control authority for clinical trials.
• General University Hospital Prague (VFN)minorStrategic or Co-development PartnerVFN's Clinical Trials and Research Department provides comprehensive administrative and professional support for clinical trial initiation and implementation, including academic IIT projects.
• European Molecular Tumour Board Network (EMTBN)minorStrategic or Co-development PartnerThe GENESIS project within CZECRIN | ONCO collaborates with EMTBN as part of international precision oncology data sharing and standardization efforts.
• PRIME ROSE (PRecisIon Cancer MEdicine RepurpOsing SystEm)minorStrategic or Co-development PartnerInternational consortium for precision cancer medicine repurposing using pragmatic clinical trials. The GENESIS project collaborates with PRIME ROSE on data sharing and treatment approach analysis.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• ICON plc: Major global CRO offering full-service clinical development, laboratory, and consulting services. Comparable in trial management, regulatory affairs, and biostatistics capabilities, but commercially oriented and far larger in scale than CZECRIN.
• IQVIA: Global commercial CRO and clinical trial services provider. Comparable in delivering multi-centre trial coordination, monitoring, biostatistics, and regulatory services — but operating commercially at vastly larger scale and serving pharma rather than academia.
• Medpace: Mid-to-large global CRO with therapeutic-area specialisation in oncology, cardiology, and rare disease. Comparable in CRO model and therapeutic-area focus, though operating commercially and serving industry sponsors.

Direct peers

• ECRIN-ERIC: European Clinical Research Infrastructure Network, the pan-European umbrella of which CZECRIN is the Czech national node. ECRIN coordinates multinational non-commercial clinical trials across Europe; CZECRIN performs the same function at the national level.
• F-CRIN (French Clinical Research Infrastructure Network): France's national ECRIN-ERIC node, structurally analogous to CZECRIN — multi-thematic clinical trial coordination network with disease-oriented components, investigator training, and EU project participation. Direct national-node peer.
• NIHR Clinical Research Network (UK): UK's nationally funded clinical research delivery network supporting trials across the NHS. Comparable to CZECRIN in providing investigator training, site coordination, and study delivery infrastructure for academic and industry-sponsored trials.
• KKS / KKSN (Koordinierungszentren für Klinische Studien, Germany): Network of German academic clinical trial coordination centres, the German ECRIN-ERIC equivalent. Provides methodological, regulatory, and operational support for academic trials — directly comparable mission, structure, and funder relationship.

Emerging players

• BBMRI-ERIC: European biobanking research infrastructure, partnered with CZECRIN. Comparable in ESFRI-roadmap status and national-node model, but focused on biosamples and data rather than trial delivery.
• EATRIS-ERIC: European Research Infrastructure for Translational Medicine, a sibling ESFRI infrastructure with which CZECRIN collaborates. Shares the European research-infrastructure model and overlapping investigator base, though focused on translational rather than clinical-trial delivery.

Others

• ACRP (Association of Clinical Research Professionals): Global non-profit providing clinical research professional certification and training. Comparable to CZECRIN Academy's education and certification mission, although ACRP is a membership/certification body rather than a trial-delivery infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCkqM-ku5nZ09YxGGpoX-gHg
• Facebookfacebook.com/czecrin
• LinkedInlinkedin.com/company/10909246
• Instagraminstagram.com/muni_creatic
• Xx.com/czecrin

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CZECRIN